NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR ...
Find the latest ASROCK Incorporation (3515.TW) stock quote, history, news and other vital information to help you with your stock trading and investing.
Poster presentations include dose optimization data for novel Wee1/Myt1 co-inhibitor SGR-3515 and the first characterization of SGR-4174, a novel SOS1 inhibitor Additionally, Schrödinger presented its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback